17
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T34168 | PROTAC-I | PROTAC I | |
PROTAC-I targets steroid hormone receptors for ubiquitination and degradation. | |||
T13086 | I-BET762 carboxylic acid | Molibresib carboxylic acid,PROTAC BRD4-binding moiety 2,GSK525762A carboxylic acid | Epigenetic Reader Domain |
I-BET762 carboxylic acid is an inhibitor of BRD4(pIC50 of 5.1). | |||
T40000 | Pomalidomide-C3-I | Others | |
Pomalidomide-C3-I is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology. | |||
T40008 | Pomalidomide-C6-I TFA | Others | |
Pomalidomide-C6-I TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology. | |||
T39901 | PROTAC IRAK4 degrader-4 | PROTAC IRAK4 degrader-4 | |
PROTAC IRAK4 degrader-4 (US20190192668A1, compound I-127) is a Cereblon-based PROTAC specifically designed to target and degrade interleukin-1 receptor-associated kinase 4 (IRAK4). | |||
T74411 | PROTAC IRAK4 degrader-7 | ||
PROTAC IRAK4 degrader-7 (Compound I-417) is an orally administered agent with antitumor properties, functioning as a PROTAC IRAK4 degrader [1]. | |||
T39679 | Lenalidomide-I | ||
Lenalidomide-I (Compound 72) is a derivative of the cereblon (CRBN) ligand, Lenalidomide, with affinity for E3 ubiquitin ligase. It facilitates the recruitment of CRBN protein. Lenalidomide-I can be utilized in PROTACs, ... | |||
T39315 | I-PEG5-OH | I-PEG5-OH | |
I-PEG5-OH is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within ... | |||
T38772 | I-PEG6-OH | I-PEG6-OH | |
I-PEG6-OH is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within ... | |||
T74454 | JPS016 | ||
JPS016, a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC), effectively degrades class I histone deacetylase (HDAC). It serves as a potent HDAC1/2 degrader, resulting in a signific... | |||
T74456 | JPS036 | ||
JPS036, a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC), efficiently degrades class I histone deacetylase (HDAC), particularly HDAC1/2. Its activity results in a substantial inc... | |||
T77938 | JPS016 TFA | HDAC | |
JPS016, a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC), effectively degrades class I histone deacetylase (HDAC), particularly HDAC1/2. This activity is associated with a substa... | |||
T78956 | PROTAC BRD3/BRD4-L degrader-2 | Epigenetic Reader Domain | |
PROTAC BRD3/BRD4-L degrader-2, a PROTAC molecule, selectively degrades cellular BRD3 and BRD4-L with K i values of 16.91 and 2.8 nM, respectively, and exhibits robust antitumor activity in mouse xenograft models, serving... | |||
T74453 | JPS014 | ||
JPS014, a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC), effectively degrades class I histone deacetylase (HDAC), exhibiting potency as an HDAC1/2 degrader. This correlation is ... | |||
T77937 | JPS014 TFA | HDAC | |
JPS014 TFA, a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC), effectively degrades class I histone deacetylase (HDAC), particularly HDAC1/2. This activity is associated with a hi... | |||
T74455 | JPS035 | ||
JPS035, a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC), effectively degrades class I histone deacetylase (HDAC), specifically HDAC1/2. Its potent activity is associated with an... | |||
T79034 | GXF-111 | Epigenetic Reader Domain | |
GXF-111, a proteolysis targeting chimera (PROTAC) molecule, efficiently induces the selective degradation of the BRD3 and BRD4-L proteins. It exhibits high binding affinities to both BRD3 BD1 and BRD3 BD2, with K i value... |